ECSP21069105A - Anticuerpos anti-trem2 y métodos para utilizarlos - Google Patents

Anticuerpos anti-trem2 y métodos para utilizarlos

Info

Publication number
ECSP21069105A
ECSP21069105A ECSENADI202169105A ECDI202169105A ECSP21069105A EC SP21069105 A ECSP21069105 A EC SP21069105A EC SENADI202169105 A ECSENADI202169105 A EC SENADI202169105A EC DI202169105 A ECDI202169105 A EC DI202169105A EC SP21069105 A ECSP21069105 A EC SP21069105A
Authority
EC
Ecuador
Prior art keywords
trem2
methods
trem2 antibodies
antibodies
antibody
Prior art date
Application number
ECSENADI202169105A
Other languages
English (en)
Inventor
Rachel Prorok
Kathryn M Monroe
Sherie Duncan
Ju Shi
Joshua I Park
Mark S Dennis
Ankita Srivastava
Kathleen Lisaingo
Lengerich Bettina Van
Riley Walsh
Original Assignee
Denali Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Denali Therapeutics Inc filed Critical Denali Therapeutics Inc
Publication of ECSP21069105A publication Critical patent/ECSP21069105A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

En un aspecto, se proporcionan anticuerpos que se unen específicamente a un receptor de activación expresado en la proteína de células mieloides 2 (TREM2). En algunas modalidades, el anticuerpo disminuye los niveles de TREM2 soluble (sTREM2). En algunas modalidades, el anticuerpo mejora la actividad de TREM2.
ECSENADI202169105A 2019-02-20 2021-09-17 Anticuerpos anti-trem2 y métodos para utilizarlos ECSP21069105A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962808141P 2019-02-20 2019-02-20

Publications (1)

Publication Number Publication Date
ECSP21069105A true ECSP21069105A (es) 2021-11-18

Family

ID=69844940

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202169105A ECSP21069105A (es) 2019-02-20 2021-09-17 Anticuerpos anti-trem2 y métodos para utilizarlos

Country Status (21)

Country Link
US (2) US20220073609A1 (es)
EP (1) EP3927743A1 (es)
JP (2) JP7543290B2 (es)
KR (1) KR20210135518A (es)
CN (1) CN113614110B (es)
AR (1) AR118144A1 (es)
AU (1) AU2020226754A1 (es)
BR (1) BR112021015656A2 (es)
CA (1) CA3130086A1 (es)
CL (1) CL2021002206A1 (es)
CO (1) CO2021012230A2 (es)
EA (1) EA202192294A1 (es)
EC (1) ECSP21069105A (es)
IL (1) IL285651A (es)
MA (1) MA55025A (es)
MX (1) MX2021009722A (es)
PE (1) PE20211979A1 (es)
PH (1) PH12021552002A1 (es)
SG (1) SG11202108734VA (es)
TW (1) TWI879756B (es)
WO (2) WO2020172457A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
AU2019404098A1 (en) * 2018-12-18 2021-05-27 Boehringer Ingelheim Io Canada Inc. FLT3 agonist antibodies and uses thereof
CN113614110B (zh) 2019-02-20 2025-03-25 戴纳立制药公司 抗trem2抗体及其使用方法
AU2021208482B2 (en) * 2020-01-13 2025-12-11 Denali Therapeutics Inc. Anti-TREM2 antibodies and methods of use thereof
KR20230093010A (ko) * 2020-10-21 2023-06-26 이뮨-온크 테라퓨틱스, 인코포레이티드 신규 항-lilrb2 항체 및 유도체 생성물
JP2024518545A (ja) * 2021-05-14 2024-05-01 ジェネンテック， インコーポレイテッド Ｔｒｅｍ２のアゴニスト
CN118765204A (zh) 2022-02-23 2024-10-11 艾利妥 抗trem2抗体的使用方法
US20250215077A1 (en) 2022-03-28 2025-07-03 Denali Therapeutics Inc. Monovalent anti-trem2 binding molecules and methods of use thereof
WO2023192282A1 (en) 2022-03-28 2023-10-05 Denali Therapeutics Inc. Methods for treating brain glucose hypometabolism
CN120603851A (zh) 2023-01-30 2025-09-05 伊萨尔生物科学有限责任公司 用于治疗神经退行性疾病的人抗trem2抗体
CN121666400A (zh) 2023-08-09 2026-03-13 豪夫迈·罗氏有限公司 单特异性和多特异性抗trem2抗体、其方法和用途
WO2025032069A1 (en) 2023-08-09 2025-02-13 F. Hoffmann-La Roche Ag Mono and multispecific anti-trem2 antibodies, methods and uses thereof
US20250101101A1 (en) 2023-09-01 2025-03-27 iTeos Belgium SA Anti-trem2 antibodies and methods of use
WO2025106361A1 (en) * 2023-11-15 2025-05-22 Merck Sharp & Dohme Llc Human nectin-4 binders

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
US8231878B2 (en) 2001-03-20 2012-07-31 Cosmo Research & Development S.P.A. Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US20120016112A1 (en) 2009-01-06 2012-01-19 Nestec S.A. Processing of macronutrients
SG173705A1 (en) 2009-03-05 2011-09-29 Abbott Lab Il-17 binding proteins
US10087408B2 (en) 2010-07-07 2018-10-02 The University Of British Columbia System and method for microfluidic cell culture
US9188593B2 (en) 2010-07-16 2015-11-17 The University Of British Columbia Methods for assaying cellular binding interactions
AU2012274461A1 (en) * 2011-06-20 2014-01-16 Kyowa Hakko Kirin Co., Ltd. Anti-erbB3 antibody
FI3677591T3 (fi) 2013-04-29 2023-04-03 Teva Pharmaceuticals Australia Pty Ltd Anti-cd38-vasta-aineet ja fuusiot heikennetylle interferonille alfa-2b
CA2922979A1 (en) 2013-09-03 2015-03-12 Novimmune S.A. Readily isolated bispecific binding molecules with native format having mutated constant regions
CN105218669A (zh) 2014-06-10 2016-01-06 河北翰林生物科技有限公司 制备抗人r47h-trem2突变体的人单克隆抗体的方法
EA201790342A1 (ru) * 2014-08-08 2017-07-31 ЭЛЕКТОР ЭлЭлСи Антитела к trem2 и способы их применения
IL283834B (en) 2014-09-28 2022-07-01 Univ California Modulation of stimulatory and non-stimulatory myeloid cells
EP3973980A1 (en) * 2015-03-31 2022-03-30 F. Hoffmann-La Roche AG Antigen binding molecules comprising a trimeric tnf family ligand
WO2017058866A1 (en) * 2015-09-28 2017-04-06 Precision Immune, Inc. Anti-trem2 antibodies and uses thereof
SG10201912150TA (en) * 2015-10-06 2020-02-27 Alector Llc Anti-trem2 antibodies and methods of use thereof
US11066456B2 (en) 2016-02-25 2021-07-20 Washington University Compositions comprising TREM2 and methods of use thereof
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
CA3030785A1 (en) 2016-07-22 2018-01-25 Deutsches Zentrum Fur Neurodegenerative Erkrankungen E.V. (Dzne) Trem2 cleavage modulators and uses thereof
EP3559043A4 (en) 2016-12-23 2020-08-05 Bluefin Biomedicine, Inc. ANTI-SEZ6L2 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES
US20190367623A1 (en) 2017-01-17 2019-12-05 Yeda Research And Development Co. Ltd. Methods of treating neurodegenerative diseases by inducing disease-associated microglia (dam) cells
US10457717B2 (en) 2017-02-17 2019-10-29 Denali Therapeutics Inc. Engineered polypeptides
ES2932759T3 (es) 2017-02-17 2023-01-25 Denali Therapeutics Inc Polipéptidos de unión al receptor de transferrina diseñados
JP2020508054A (ja) 2017-02-17 2020-03-19 デナリ セラピューティクス インコーポレイテッドＤｅｎａｌｉ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． 抗タウ抗体及びその使用方法
JOP20190248A1 (ar) * 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
BR112020001060A2 (pt) 2017-07-27 2020-07-14 Novartis Ag variantes de trem2 resistentes a shedase
MD3601358T2 (ro) 2017-08-03 2023-10-31 Alector Llc Anticorpi anti-TREM2 și metode de utilizare a acestora
EP3665194A4 (en) 2017-08-10 2021-07-07 Denali Therapeutics Inc. AFFINITY BASED METHODS FOR USING TRANSFERRIN RECEPTOR BINDING PROTEINS
JP7403441B2 (ja) 2017-09-14 2023-12-22 デナリ セラピューティクス インコーポレイテッド 抗ｔｒｅｍ２抗体及びその使用方法
MA50746A (fr) 2017-10-02 2020-08-12 Denali Therapeutics Inc Protéines de fusion comprenant des enzymes d'enzymothérapie substitutive
US20210186917A1 (en) 2017-10-17 2021-06-24 The Translational Genomics Research Institute Trem2 agonists for the stimulation of microglia and methods of identification
WO2019094608A1 (en) 2017-11-08 2019-05-16 Denali Therapeutics Inc. Anti-bace1 antibodies and methods of use thereof
CA3083660A1 (en) 2017-12-12 2019-06-20 Pionyr Immunotherapeutics, Inc. Anti-trem2 antibodies and related methods
WO2019140050A1 (en) 2018-01-10 2019-07-18 Denali Therapeutics Inc. Transferrin receptor-binding polypeptides and uses thereof
US20210284702A1 (en) 2018-06-18 2021-09-16 Denali Therapeutics Inc. Fusion proteins comprising progranulin
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
CN112839955A (zh) 2018-08-16 2021-05-25 戴纳立制药公司 经工程改造双特异性蛋白
TW202017947A (zh) 2018-08-22 2020-05-16 美商戴納立製藥公司 抗her2 多肽及其使用方法
BR112021004316A2 (pt) 2018-09-11 2021-11-03 Washington University St Louis Anticorpos de agonistas anti-trem-2
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
KR102156165B1 (ko) 2018-10-29 2020-09-15 재단법인대구경북과학기술원 인간 ｔｒｅｍ２ 세포막 단백질에 대한 단일클론항체, 이를 생산하는 하이브리도마 세포주 및 이의 용도
MA54296A (fr) 2018-11-26 2021-10-06 Denali Therapeutics Inc Procédés de traitement du métabolisme lipidique dérégulé
EP3898691A4 (en) 2018-12-10 2022-09-14 Mor Research Applications TREM2 ANTIBODIES AND USES THEREOF
MA54450A (fr) 2018-12-10 2021-10-20 Denali Therapeutics Inc Biomarqueurs de maladie lysosomale et leurs méthodes d'utilisation
EP3893931A4 (en) 2018-12-11 2022-09-07 Pionyr Immunotherapeutics, Inc. METHODS FOR USE OF ANTI-TREM2 ANTIBODIES
CN113614110B (zh) 2019-02-20 2025-03-25 戴纳立制药公司 抗trem2抗体及其使用方法
WO2020194317A1 (en) 2019-03-28 2020-10-01 Yeda Research And Development Co. Ltd. Method of treating lipid-related disorders
KR20220004651A (ko) 2019-04-03 2022-01-11 데날리 테라퓨틱스 인크. 이두로네이트 2-설파타제를 포함하는 단백질 분자의 제제
AU2020411480B2 (en) 2019-12-23 2023-12-21 Denali Therapeutics Inc. Progranulin variants
AU2021208482B2 (en) 2020-01-13 2025-12-11 Denali Therapeutics Inc. Anti-TREM2 antibodies and methods of use thereof
WO2021146256A1 (en) 2020-01-13 2021-07-22 Denali Therapeutics Inc. Anti-trem2 antibodies and methods of use thereof
EP4100419A4 (en) 2020-02-07 2024-05-29 Denali Therapeutics Inc. METHODS OF TREATING HUNTER SYNDROME
BR112022016232A2 (pt) 2020-02-19 2022-11-16 Denali Therapeutics Inc Proteínas biespecíficas anti-her2 manipuladas
CR20230178A (es) 2020-10-14 2023-07-26 Denali Therapeutics Inc Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas

Also Published As

Publication number Publication date
EA202192294A1 (ru) 2021-12-24
EP3927743A1 (en) 2021-12-29
JP2024164116A (ja) 2024-11-26
IL285651A (en) 2021-09-30
US20220119522A1 (en) 2022-04-21
TW202045543A (zh) 2020-12-16
AU2020226754A1 (en) 2021-09-16
TWI879756B (zh) 2025-04-11
MA55025A (fr) 2021-12-29
CO2021012230A2 (es) 2021-09-30
MX2021009722A (es) 2021-09-14
CN113614110A (zh) 2021-11-05
PH12021552002A1 (en) 2022-09-19
AR118144A1 (es) 2021-09-22
JP2022520868A (ja) 2022-04-01
US20220073609A1 (en) 2022-03-10
KR20210135518A (ko) 2021-11-15
US12240902B2 (en) 2025-03-04
BR112021015656A2 (pt) 2021-10-05
CL2021002206A1 (es) 2022-04-22
CN113614110B (zh) 2025-03-25
JP7543290B2 (ja) 2024-09-02
WO2020172450A1 (en) 2020-08-27
SG11202108734VA (en) 2021-09-29
WO2020172457A1 (en) 2020-08-27
CA3130086A1 (en) 2020-08-27
PE20211979A1 (es) 2021-10-05

Similar Documents

Publication Publication Date Title
ECSP21069105A (es) Anticuerpos anti-trem2 y métodos para utilizarlos
CO2022009744A2 (es) Anticuerpos anti-trem2 y métodos para utilizarlos
CL2019003093A1 (es) Anticuerpos anti-trem2 y métodos para utilizarlos.
ES2527961T3 (es) Anticuerpos monoclonales humanos para CD70
CL2021001368A1 (es) Anticuerpos biespecíficos anti-pd-l1/anti-4-1bb y usos de los mismos
CL2022001886A1 (es) Anticuerpos anti-trem2 y métodos para utilizarlos
CO2021004560A2 (es) Anticuerpos estabilizadores de trem2
CL2021001506A1 (es) Anticuerpos que se unen a cd3
MX2024005009A (es) Dominios de union anti-cd3 y anticuerpos que los comprenden, y metodos para su generacion y uso.
UY37083A (es) Anticuerpos anti-ror1, anticuerpos biespecíficos ror1 x cd3 y métodos para su uso
MX2020004129A (es) Anticuerpos anti-cd38 y metodos de uso.
UY37758A (es) Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
AR069775A1 (es) Anticuerpos bivalentes biespecificos
CO2022009737A2 (es) Anticuerpos anti-ly6g6d y métodos de uso
CO2022008272A2 (es) Agentes de unión a ilt3 y métodos de uso de los mismos
PE20140673A1 (es) Nuevos moduladores y metodos para su uso
MX2021004284A (es) Anticuerpos anti-npr1 y usos de los mismos.
MX2016008196A (es) Anticuerpos y metodos de uso.
BR112021021645A2 (pt) Anticorpos anti-hvem e uso dos mesmos.
CO2019009035A2 (es) Proteínas de unión al receptor de glucagón y métodos para usarlas
AR122930A1 (es) Anticuerpos de pre-direccionamiento y métodos de uso
MX2025005542A (es) Moléculas antagonistas de fcrn y métodos de uso de estas
CL2025002112A1 (es) Anticuerpo anti-npr1; método de producción; y su uso.
PE20191743A1 (es) Anticuerpos biespecificos anti-pd-l1-anti-tim3
MX2017014911A (es) Fragmento fab de anticuerpo ngf anti-humano novedoso.